KHKathrin Heinrich

Kathrin Heinrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathrin Heinrich has a total of 277 co-authors. Here are the top co-authors by number of shared publications:

  • Volker Heinemann

    Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany

    11 shared publications
  • Sebastian Stintzing

    Department of Hematology, Oncology and Cancer Immunology, Charité—Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    9 shared publications
  • Dominik Paul Modest

    Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    7 shared publications
  • Michael von Bergwelt-Baildon

    Department of Medicine III, LMU University Hospital Munich , Munich, 81377

    7 shared publications
  • Volker Heinemann

    Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, Germany

    7 shared publications
  • Arndt Stahler

    Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany

    6 shared publications

Latest Publications

  • Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK

    by Karin Potthoff, Sebastian Lange, Thomas Seufferlein, Kathrin Heinrich, Rainer Claus, Annalen Bleckmann, Matthias Zaiss, Corinne Vannier, Sina Grebhardt, Sophie Koszinowski, et al.

    PURPOSE: TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion–positive tumors. However, approval of TRKis is based on evidence derived mainly from small, pooled, single-arm clinical trial cohorts. The REALTRK registry aims to describe real-world molecular diagnostic practices, treatment patterns, and clinical outcomes for adult patients with NTRK fusion–positive cancers. PATIENTS AND METHODS: The REALTRK registry was a multicenter cohort study that included adults with advanced solid tumors harboring NTRK1 / 2 / 3 fusions, from Germany and Switzerland. Both retrospective and prospective data were collected from diverse clinical settings. NTRK fusions had to be diagnosed via validated assays. RESULTS: Of 88 patients screened, 47 adults with advanced NTRK fusion–positive solid tumors were included in the full analysis set. Across all treatment lines after NTRK fusion diagnosis, 29 patients received TRKi therapy, eight received non-TRKi therapy, and 10 received no therapy. Lung cancer, colorectal cancer, and soft tissue sarcoma were the most common tumor types. Next-generation sequencing was the primary diagnostic method, with a median turnaround time of 2 weeks. After NTRK fusion diagnosis, TRKi therapy was immediately initiated in 26 patients, of whom 13 received TRKi as first-line treatment in the advanced/metastatic setting. About half of the patients responded to TRKi treatment as the first treatment line after NTRK fusion diagnosis (46.2%), with an overall response rate of 46.2% and a disease control rate of 73.1%. The median progression-free survival was 15.7 months, and the overall survival was 27.6 months in TRKi-treated patients. CONCLUSION: The REALTRK registry provides important real-world insights into the patient path of adult patients with locally advanced or metastatic solid tumors harboring NTRK1 / 2 / 3 gene fusions.

  • Open Access

    Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E–mutant rectal cancer with bowel obstruction

    by Maximilian Alexander Funk, Volker Heinemann, Veit Bücklein, Stefan Karl Alig, Kathrin Heinrich, Lena Weiss, Victoria Krenmayr, Benoit Blanchet, Wolfgang Gerhard Kunz, Sebastian Theurich, et al.

    The activating BRAF mutation V600E occurs in 8%–12% of metastatic colorectal cancers (mCRC) and is associated with peritoneal carcinomatosis (PC) and poor prognosis. Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial. We report a 26-year-old male with rapidly progressive, BRAF V600E-mutant, microsatellite-stable (MSS) rectal adenocarcinoma, liver metastases, and PC presenting with bowel obstruction and inability for oral intake. To enable targeted therapy, encorafenib was administered rectally and via nasogastric tube, together with intravenous cetuximab and FOLFOX (FOLFOX+EC). Most adverse events (AEs) were present before treatment and improved during FOLFOX+EC, indicating tumor association. Severe AEs included emesis, fatigue, pain, and elevated cholestatic liver enzymes. Treatment-related AEs were manageable with anaemia (°3), neutropenia (°4), and thrombocytopenia (°1). No encorafenib-specific toxicities (rash, pyrexia, QTc prolongation, or ocular effects) were observed. Pharmacokinetic analysis showed trough plasma exposure comparable to oral dosing in patients without PC, and CT imaging at weeks 4 and 8 revealed early tumor shrinkage. This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in the context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.


  • Open Access

    Geschlechtersensible Krebsmedizin – Bedeutung biologischer und psychosozialer Unterschiede für Tumorentstehung, Therapie und Prognose

    by Kathrin Heinrich

    Biologische Geschlechtsmerkmale und psychosoziale Genderfaktoren beeinflussen nahezu alle Bereiche der Onkologie und gewinnen im Kontext der personalisierten Medizin zunehmend an Bedeutung. Neuere Erkenntnisse zeigen, dass Unterschiede in Genexpression, Immunantwort, Pharmakokinetik und Medikamententoleranz das Tumorrisiko, den Krankheitsverlauf und den Therapieerfolg maßgeblich prägen. Gleichzeitig tragen soziale Rollenbilder, Gesundheitsverhalten und Versorgungsstrukturen wesentlich zur Ausprägung von Risiken, Präventionslücken und Therapieadhärenz bei. Der vorliegende Artikel fasst aktuelle Erkenntnisse der geschlechtersensiblen Onkologie zusammen, stellt Zusammenhänge zwischen Sex- und Genderfaktoren dar und diskutiert Konsequenzen für Forschung und klinische Praxis. Article published online: 11 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial

    by Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, et al.


  • Open Access

    Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

    by Klara Dorman, Christoph J. Auernhammer, Christine Spitzweg, Ralf Schmidmaier, Svenja Nölting, Matthias Kroiss, Martin Reincke, Christian Schulz, Martin Angele, Jens Werner, et al.

  • Open Access

    Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

    by Klara Dorman, Christoph J. Auernhammer, Christine Spitzweg, Ralf Schmidmaier, Svenja Nölting, Matthias Kroiss, Martin Reincke, Christian Schulz, Martin Angele, Jens Werner, et al.

    Background Comprehensive genomic profiling (CGP) has become more generally accessible to patients with rare cancer, but data on the results and benefits are limited. Objective Our objective was to gain a real-world understanding of the molecular landscape and targeted treatment options in neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids. Patients and Methods In this retrospective cohort study, we analyzed CGP results and clinical data from patients with neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids who were discussed in the CCCMunichLMU Molecular Tumor Board (MTB) between May 2017 and April 2023. Results In total, 104 patients with endocrine and neuroendocrine neoplasms were discussed in the MTB. CGP was technically successful in 99 patients. The most commonly mutated genes were TP53 (29.3%), RB1 (11.1%), and KRAS (10.1%). The highest overall prevalence of pathogenic alterations was detected in neuroendocrine carcinomas (76.9%) and carcinoids (83.3%), and the lowest prevalence of pathogenic alterations was seen in adrenocortical carcinoma (37.5%). Of the 99 patients with successful CGP, 35 received a treatment recommendation from the MTB based on the CGP results. Of these, ten patients ultimately received the recommended treatment. Of the ten treated patients, four experienced a longer progression-free survival under the targeted treatment than under their previous treatment. Conclusions One-third of patients with rare endocrine and neuroendocrine neoplasms who underwent CGP had a druggable alteration and received a treatment recommendation from the MTB. However, only 28.6% of these patients were treated accordingly. Our experience highlights the unmet medical need for targeted treatment options in patients with rare cancers.


  • Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study

    by Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Kathrin Heinrich, Dominik Paul Modest, Ralf-Dieter Hofheinz, Thomas Decker, Armin Gerger, et al.

    PURPOSE: The FIRE-4 study randomly assigned patients with first-line RAS wild-type ( RAS wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) or to FOLFIRI plus cetuximab followed by a switch maintenance treatment using FU plus bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) RAS and BRAF testing compared with tissue-based analyses. PATIENTS AND METHODS: LBs were taken at baseline and during treatment and were analyzed for RAS and BRAF V600E mutations using the in vitro diagnostics–certified ONCOBEAM RAS procedure (Sysmex Inostics) and digital-droplet polymerase chain reaction technology. RESULTS: Six hundred seventy-two RAS wt patients were randomly assigned. LBs of 540 patients were evaluable at baseline. Of those, 70 (13%) were RAS mutant ( RAS mut) and 38 (7%) BRAF V600E mutant. RAS mut patients had significantly shorter survival compared with RAS wt patients (progression-free survival [PFS], 9.0 months v 11.5 months; P < .001; hazard ratio [HR], 1.66; overall survival [OS], 22.1 months v 33.6 months; P < .001; HR, 1.85). RAS mut patients had a numerically greater benefit from early switch maintenance compared with continuation of FOLFIRI/cetuximab (PFS, 10.1 months v 6.4 months; HR, 0.82; OS, 24.9 months v 16.3 months; HR, 0.57). Patients with a BRAF V600E mutation in LB showed poor outcome (PFS, 5.4 months; OS, 12.0 months). On the basis of serial LB analyses, the conversion rate from RAS wt to RAS mut at disease progression was significantly higher in the arm with continuous cetuximab administration than in the switch maintenance arm. CONCLUSION: LB allows the detection of RAS and BRAF mutations in patients deemed RAS wt on the basis of tissue analyses. These patients show outcome characteristics expected for RAS - and BRAF -mutant patients in tissue. The study thus confirms the high clinical relevance of LB performed at baseline before the start of therapy.


  • Open Access

    FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters

    by Julian Walter Holch, Alexander J. Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Lena Weiss, Victoria Probst, Arndt Stahler, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, et al.


  • Open Access

    Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients

    by Phillip Schiele, Stefan Kolling, Stanislav Rosnev, Charlotte Junkuhn, Anna Luzie Walter, Jobst Christian von Einem, Sebastian Stintzing, Wenzel Schöning, Igor Maximilian Sauer, Dominik Paul Modest, et al.

    Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells is a key mechanism in anti-cancer therapies with monoclonal antibodies, including cetuximab (EGFR-targeting) and avelumab (PDL1-targeting). Fc gamma receptor IIIa (FcγRIIIa) polymorphisms impact ADCC, yet their clinical relevance in NK cell functionality remains debated. We developed two complementary flow cytometry assays: one to predict the FcγRIIIa-V158F polymorphism using a machine learning model, and a 15-color flow cytometry panel to assess antibody-induced NK cell functionality and cancer-immune cell interactions. Samples were collected from healthy donors and metastatic colorectal cancer (mCRC) patients from the FIRE-6-Avelumab phase II study. The machine learning model accurately predicted the FcγRIIIa-V158F polymorphism in 94% of samples. FF homozygous patients showed diminished cetuximab-mediated ADCC compared to VF or VV carriers. In mCRC patients, NK cell dysfunctions were evident as impaired ADCC, decreased CD16 downregulation, and reduced CD137/CD107a induction. Elevated PD1+ NK cell levels, reduced lysis of PDL1-expressing CRC cells and improved NK cell activation in combination with the PDL1-targeting avelumab indicate that the PD1-PDL1 axis contributes to impaired cetuximab-induced NK cell function. Together, these optimized assays effectively identify NK cell dysfunctions in mCRC patients and offer potential for broader application in evaluating NK cell functionality across cancers and therapeutic settings.